The introduction of inclisiran (Leqvio) in England, which is designed to lower LDL cholesterol in patients with cardiovascular disease, has achieved only around 10% of its planned target of 300,000 patients by autumn 2024. As of 2021, only around 30,000 doses of the drug have been prescribed in primary care. Inclisiran is administered by injection twice a year and is intended for patients with persistently high LDL cholesterol levels and a history of cardiovascular events. The drug was approved in the European Union in 2020 and in the United Kingdom in 2021, with NICE recommending its use in the secondary prevention of cardiovascular disease. Inclisiran works by reducing the production of the PCSK9 protein, which allows the liver to break down LDL cholesterol better, and clinical studies have shown a reduction of LDL cholesterol by around 50%. The NHS funds the drug centrally so that there are no financial barriers for patients, yet its availability is lower than originally expected[1][2][3][5].